1 Min Read
Jan 9 (Reuters) - Infinity Pharmaceuticals Inc :
* Infinity provides 2017 goals and financial guidance
* Infinity Pharmaceuticals Inc - expects to end 2017 with a year-end cash and investments balance ranging from $40 million to $50 million
* Infinity Pharmaceuticals Inc - expects net loss for 2017 to range from $40 million to $50 million.
* Infinity Pharmaceuticals - updated cash runway expectation assumes receiving $6.0 million milestone payment from verastem for positive duo study results
* Infinity Pharmaceuticals sees existing cash, cash equivalents, available-for-sale securities at Dec 31 2016 to be adequate to satisfy capital needs into Q1 2019 Source text for Eikon: Further company coverage: